Predictors of radiographic progression in univariate and multivariate Cox regression analysis
| Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|
| Baseline characteristics | p Value* | HR (95% CI) | p Value | HR (95% CI) | |
| Arthritis | Flexion contracture at baseline | 0.04 | 3.23 (1.18 to 8.82) | 0.05 | 2.42 (0.99 to 5.92) |
| Elevated sPAP | 0.02 | 6.20 (1.51 to 25.58) | 0.05 | 3.21 (0.98 to 10.30) | |
| Anticentromere antibodies | 0.1 | 1.06 (0.36 to 3.09) | 0.4 | 1.68 (0.55 to 5.17) | |
| Rheumatoid factor | 0.1 | 0.41 (0.09 to 1.75) | 0.4 | 0.52 (0.12 to 2.35) | |
| Acro-osteolysis | Age | 0.1 | 0.97 (0.94 to 1.01) | 0.7 | 1.02 (0.91 to 1.21) |
| Flexion contracture at baseline | 0.01 | 2.97 (1.29 to 6.83) | 0.09 | 2.23 (0.86 to 5.74) | |
| Calcinosis at baseline | 0.01 | 3.12 (1.31 to 7.44) | 0.03 | 6.17 (1.16 to 47.23) | |
| Diffuse cutaneous subtype | 0.09 | 2.07 (0.89 to 4.84) | 0.6 | 1.93 (0.20 to 18.24) | |
| Digital ulcers | 0.008 | 3.19 (1.37 to 7.42) | 0.01 | 12.43 (1.97 to 88.40) | |
| Elevated sPAP | 0.02 | 6.20 (1.51 to 25.58) | 0.8 | 1.13 (0.39 to 3.43) | |
| Pulmonary fibrosis | 0.03 | 2.99 (1.11 to 8.08) | 0.7 | 1.25 (0.26 to 4.21) | |
| Antitopoisomerase-1 antibodies | 0.04 | 2.46 (1.06 to 5.75) | 0.09 | 2.72 (0.91 to 8.25) | |
| HAQ >1.5 | 0.1 | 2.29 (0.74 to 7.06) | 0.2 | 4.54 (0.52 to 43.90) | |
| Calcinosis | Male | 0.02 | 2.74 (1.20 to 6.26) | 0.01 | 3.99 (1.45 to 12.13) |
| Diffuse cutaneous subtype | 0.04 | 2.05 (1.12 to 4.42) | 0.1 | 2.49 (0.83 to 7.44) | |
| History of digital ulcers | 0.01 | 2.73 (1.27 to 5.84) | 0.02 | 3.16 (1.22 to 9.43) | |
| Decreased Dlco/Va <75% predicted | 0.02 | 2.52 (1.16 to 5.49) | 0.1 | 2.09 (0.80 to 5.49) | |
| Flexion contracture | Female | 0.09 | 1.12 (0.26 to 4.85) | 0.9 | 1.39 (0.10 to 18.34) |
| Acro-osteolysis at baseline | 0.02 | 2.91 (1.10 to 7.75) | 0.08 | 2.20 (0.96 to 16.65) | |
| Arthritis at baseline | 0.01 | 3.21 (1.27 to 8.11) | 0.5 | 1.55 (0.27 to 10.07) | |
| Diffuse cutaneous subtype | 0.004 | 2.39 (1.03 to 6.15) | 0.03 | 7.52 (1.21 to 43.93) | |
| Elevated sPAP | 0.01 | 3.19 (1.12 to 9.12) | 0.4 | 3.16 (0.25 to 35.38) | |
| HAQ >1.5 | 0.04 | 3.31 (1.04 to 11.66) | 0.4 | 1.72 (0.20 to 11.56) | |
Variables with p<0.1 in univariate analysis were included in the multivariate Cox regression analysis.
Dlco/Va, decrease in carbon monoxide diffusion capacity divided by alveolar volume; HAQ, Health Assessment Questionnaire; sPAP, systolic pulmonary artery pressure.